Title
Efikasnost i bezbednost primene visokih doza alfakalcidola u lečenju aktivnog reumatoidnog artitisa
Creator
Simić-Pašalić, Katarina A. 1965-
Copyright date
2016
Object Links
Select license
Autorstvo-Nekomercijalno-Bez prerade 3.0 Srbija (CC BY-NC-ND 3.0)
License description
Dozvoljavate samo preuzimanje i distribuciju dela, ako/dok se pravilno naznačava ime autora, bez ikakvih promena dela i bez prava komercijalnog korišćenja dela. Ova licenca je najstroža CC licenca. Osnovni opis Licence: http://creativecommons.org/licenses/by-nc-nd/3.0/rs/deed.sr_LATN. Sadržaj ugovora u celini: http://creativecommons.org/licenses/by-nc-nd/3.0/rs/legalcode.sr-Latn
Language
Serbian
Cobiss-ID
Theses Type
Doktorska disertacija
description
Datum odbrane: 08.07.2016.
Other responsibilities
mentor
Vojinović, Jelena 1965-
član komisije
Stamenković, Bojana
član komisije
Damjanov, Nemanja 1955-
Academic Expertise
Medicinske nauke
University
Univerzitet u Nišu
Faculty
Medicinski fakultet
Group
Katedra za fizikalnu medicinu i rehabilitaciju i medicinu rada
Alternative title
Efficacy and safety of active rheumatoid arthritis treatment with high doses of alphacalcidol
Publisher
[K. Simić-Pašalić]
Format
134 lista
description
Biografija : list 131
description
Skeleton, muscles, rheumatology, locomotion
Abstract (en)
In a prospective, interventional study on efficacy and safety of alfacalcidol (1αD3) treatment of rheumatoid arthritis (RA), 67 patients with active RA were included,treated for at least three months before inclusion with the highest tolerated dose of methotrexate (MTX), with no associated disease or therapy of influence to inflammation or calcium metabolism. After signing the written consent, samples were taken for biochemical and immunoserological testing, also urine for daily calciuria, activity of RA, functional status, life quality, fatigue, muscle strength and function were assessed, bone mass and quality were examined. Patients were randomly assigned to treatment with 1 μg, 2μg, 3μg 1αD3 daily or 20mg of prednisone daily for the first month, and 10 mg during the next two months. They were monitored at 2-4 week for insight into the efficacy and safety of treatment used. After the completion of this research period, clinical and laboratory data obtained were compared with initial ones in each group, as well as to each other. All patients continued investigation taking 1μ 1αD3 daily, for 9 months. Three month treatment either 1 μg, 2μg, 3μg 1αD3 or prednisone significantly decreased RA activity and in 1αD3 2μg subgroup to improved functional ability, physical and mental quality of life, muscle power and coordination, reduction of biochemical parameters of inflammation, interleukin 6, increase of HDL cholesterol, with moderate increase of daily calciuria. At the end of follow up, the loss of bone mass was found in patients treated with prednisone, yet improvementof the quality of the bone in alfacalcidol treated ones.
Authors Key words
reumatoidni artritis, vitamin D, alfakalcidol, citokini, steroidi
Authors Key words
rheumatoid arthritis, vitamin D, alphacalcidol, cytokines, steroides
Classification
616.72-002.77:615.356.015.3(043.3)
Subject
B580, B 500
Type
Elektronska teza
Abstract (en)
In a prospective, interventional study on efficacy and safety of alfacalcidol (1αD3) treatment of rheumatoid arthritis (RA), 67 patients with active RA were included,treated for at least three months before inclusion with the highest tolerated dose of methotrexate (MTX), with no associated disease or therapy of influence to inflammation or calcium metabolism. After signing the written consent, samples were taken for biochemical and immunoserological testing, also urine for daily calciuria, activity of RA, functional status, life quality, fatigue, muscle strength and function were assessed, bone mass and quality were examined. Patients were randomly assigned to treatment with 1 μg, 2μg, 3μg 1αD3 daily or 20mg of prednisone daily for the first month, and 10 mg during the next two months. They were monitored at 2-4 week for insight into the efficacy and safety of treatment used. After the completion of this research period, clinical and laboratory data obtained were compared with initial ones in each group, as well as to each other. All patients continued investigation taking 1μ 1αD3 daily, for 9 months. Three month treatment either 1 μg, 2μg, 3μg 1αD3 or prednisone significantly decreased RA activity and in 1αD3 2μg subgroup to improved functional ability, physical and mental quality of life, muscle power and coordination, reduction of biochemical parameters of inflammation, interleukin 6, increase of HDL cholesterol, with moderate increase of daily calciuria. At the end of follow up, the loss of bone mass was found in patients treated with prednisone, yet improvementof the quality of the bone in alfacalcidol treated ones.
“Data exchange” service offers individual users metadata transfer in several different formats. Citation formats are offered for transfers in texts as for the transfer into internet pages. Citation formats include permanent links that guarantee access to cited sources. For use are commonly structured metadata schemes : Dublin Core xml and ETUB-MS xml, local adaptation of international ETD-MS scheme intended for use in academic documents.